Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of eculizumab versus placebo in Guillain-Barre syndrome
jRCT2031200420Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Guillain-Barré syndrome (GBS) comparing Eculizumab + IVIg with Placebo + IVIg (2 arms). Primary endpoint: Time to first reaching a Hughes Functional Grade score of 1 or less. Started Mar 2021; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on jRCT2031200420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200420.